文献速递糖尿病

载脂蛋白M与2型糖尿病风险

Apolipoprotein M and Risk of Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究采用前瞻性设计结合孟德尔随机化,在丹麦哥本哈根城市心脏研究(CCHS,n=8589)和哥本哈根普通人群研究(CGPS,n=93857)中分析血浆载脂蛋白M(apoM)与2型糖尿病风险的关系。观察性分析显示血浆apoM最高四分位组较低四分位组(参照)风险比=0.32(95%CI=0.1-1.01;趋势P=.02)。基因变异rs1266078与apoM浓度降低10.8%(P=6.2×10-5)相关,但纳入599 451人的荟萃分析显示rs1266078与2型糖尿病风险无关联。结论为不支持血浆apoM与2型糖尿病风险存在因果关联。

要点

  • 血浆apoM最高四分位组较最低四分位组2型糖尿病风险比=0.32(95%CI=0.1-1.01;趋势P=.02)。
  • rs1266078变异与血浆apoM浓度降低10.8%相关(P=6.2×10-5)。
  • 纳入599 451人的荟萃分析显示rs1266078与2型糖尿病风险无关联。

核心结论

  • 本研究似乎不支持血浆apoM与2型糖尿病风险之间存在因果关联。

研究设计与样本

  • 前瞻性研究设计,采用孟德尔随机化分析。
  • 研究人群为反映丹麦一般人群的两个队列:哥本哈根城市心脏研究(CCHS,n=8589)和哥本哈根普通人群研究(CGPS,n=93857)。
  • 观察性分析纳入CCHS中有血浆apoM数据的部分参与者(n=725);遗传学分析纳入完整队列(n=102 446)。
  • 中位随访时间CCHS为16年、CGPS为8年,期间分别有563和2132名参与者发生2型糖尿病。

主要发现

  • 在CCHS部分参与者中,血浆apoM最高四分位组与最低四分位组(参照)相比,2型糖尿病风险比=0.32(95%CI=0.1-1.01;趋势P=.02)。
  • APOM特定单核苷酸多态性基因分型显示,携带rs1266078变异的参与者血浆apoM浓度降低10.8%(P=6.2×10-5)。
  • 一项纳入599 451人的荟萃分析显示,rs1266078与2型糖尿病风险之间无关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Recent studies have discovered a role of apolipoprotein M (apoM) in energy metabolism, and observational analyses in humans suggest an association with type 2 diabetes. The causal relationship remains however elusive. OBJECTIVE: To investigate whether reduced plasma apoM concentrations are causally linked to increased risk of type 2 diabetes. DESIGN: Prospective study design analyzed by Mendelian randomization. SETTING AND PARTICIPANTS: Two cohorts reflecting the Danish general population: the Copenhagen City Heart Study (CCHS, n = 8589) and the Copenhagen General Population Study (CGPS; n = 93 857). Observational analyses included a subset of participants from the CCHS with available plasma apoM (n = 725). Genetic analyses included the complete cohorts (n = 102 446). During a median follow-up of 16 years (CCHS) and 8 years (CGPS), 563 and 2132 participants developed type 2 diabetes. MAIN OUTCOME MEASURES: Plasma apoM concentration, genetic variants in APOM, and type 2 diabetes. RESULTS: First, we identified an inverse correlation between plasma apoM and risk of type 2 diabetes in a subset of participants from the CCHS (hazard ratio between highest vs lowest quartile (reference) = 0.32; 95% confidence interval = 0.1-1.01; P for trend = .02). Second, genotyping of specific single nucleotide polymorphisms in APOM further revealed a 10.8% (P = 6.2 × 10-5) reduced plasma apoM concentration in participants with variant rs1266078. Third, a meta-analysis including data from 599 451 individuals showed no association between rs1266078 and risk of type 2 diabetes. CONCLUSIONS: The present study does not appear to support a causal association between plasma apoM and risk of type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hajny S, Christoffersen M, Dalila N, et al. Apolipoprotein M and Risk of Type 2 Diabetes. J Clin Endocrinol Metab. 2020. PMID: 32621749. doi:10.1210/clinem/dgaa433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。